Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1

Interventions

pembrolizumab 1024Carboplatin 966Paclitaxel 933Gemcitabine 794Cisplatin 753Docetaxel 684Bevacizumab 609Pemetrexed 504Nivolumab 487Cyclophosphamide 474Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 373Oxaliplatin 348Injections 347atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 246Doxorubicin 241Ipilimumab 226fludarabine 220Lenalidomide 220Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Catalytic Domain × Clear all
NCT06056323 2023-10-23

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 1/2 Unknown
71 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡